Table 4.

Subgroup analysis and exploration of heterogeneity in CD22 CAR-T clinical trials

Patients with available data	Overall response rate	Complete response rate	negative Minimal residual disease	Cytokine release syndrome	≥ Grade 3 cytokine release syndrome	Neurotoxicity	≥ Grade 3 neurotoxicity	Relapse rate	CD22 dim/negative relapse rate
Age Group
Children (N = 114)	76% (68–83)	74% (65–81)	-	87% (80–92)	6% (3–12)	28% (21–37)	-	36% (18–54)	16% (0–32)
Adult (N = 37)	75% (59–87)	57% (41–72)	-	84% (68–93)	5% (1–19)	11% (4–25)	-	6% (0–20)	3% (0–9)
p value	0.94	0.05*	-	0.6	0.9	0.04*	-	0.01**	0.14
Bone marrow involvement (B-ALL)
High burden (N = 98)	74% (65–82)	63% (43–83)	66% (55–75)	86% (78–92)	7% (3–14)	25% (17–34)	1% (0–7)	23% (6–58)	8% (1–46)
Low burden (N = 25)	81% (66–96)	76% (59–93)	68% (48–83)	88% (69–96)	4% (1–24)	32% (17–52)	4% (1–24)	40% (23–60)	12% (4–31)
p value	0.22	0.54	0.82	0.81	0.6	0.46	0.32	0.37	0.73
Disease
B-ALL (N = 133)	76% (69–83)	72% (65–80)	-	87% (82–93)	4% (1–8)	20% (8–32)	1% (0–3)	31% (13–49)	11% (0–23)
B cell lymphoma (N = 28)	86% (73–99)	64% (47–82)	-	74% (19–100)	4% (0–12)	10% (0–28)	0% (0–6)	8% (0–19)	4% (0–12)
p value	0.19	0.41	-	< 0.01**	0.87	0.36	0.75	0.04*	0.35
Prior CD19 CAR-T therapy
Yes (N = 67)	75% (65–87)	73% (62–86)	45% (16–74)	76% (62–91)	9% (3–30)	0% (0–6)	0% (0–6)	19% (0–46)	24% (9–66)
No (N = 15)	76% (58–100)	79% (58–100)	62% (22–100)	83% (62–100)	13% (3–58)	0% (0–6)	0% (0–6)	29% (5–52)	20% (7–60)
p value	0.76	0.64	0.5	0.59	0.72	1	1	0.59	0.55

Data are event rate, % (95% CI), p values, or number of patients. Adults were patients aged 20 years or older; children were patients aged younger than 20 years, CAR chimeric antigen receptor